Login Register
icon_bulk_orderBulk order Acrobiosystems for English
Recombinant Proteins ClearClear history
Recombinant Proteins CloseClose
Browse Products By Molecule Name a-zA-Z
GMP IL-15 NEW |Streptavidin（SA） Hot |Claudin 18.2 |CD3 |GPCRs
0
There is no goods in the shopping cart !
My Cart
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > PD-L1

PD-L1

Brief Information

Name:Programmed death-ligand 1
Target Synonym:HPD-L1,Programmed Cell Death 1 Ligand 1,PDCD1L1,B7H1,PDL1,Programmed Death Ligand 1,B7-H1,B7-H,B7-H1 Antigen,CD274,B7 homolog 1,PDCD1 ligand 1,PD-L1,PDCD1LG1,CD274 Molecule,CD274 Antigen
Number of Launched Drugs:5
Number of Drugs in Clinical Trials:103
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Product> Filter Results
By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
PDL-C82E8 Cynomolgus / Rhesus macaque Biotinylated Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His,Avitag™ (MALS verified)
PDL-C82E8-structure
PDL-C82E8-sds
PDL-C52H4 Canine Canine PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PDL-C52H4-structure
PDL-C52H4-sds
PD1-H82A3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Mouse IgG2a Fc,Avitag™ (MALS verified)
PD1-H82A3-structure
PD1-H82A3-sds
PD1-H52H3 Human Human PD-L1 / B7-H1 (19-134) Protein, His Tag (MALS verified)
PD1-H52H3-structure
PD1-H52H3-sds
PD1-C52H3 Canine Canine PD-L1 / B7-H1 Protein, Fc Tag
PD1-C52H3-structure
PD1-C52H3-sds
PDL-H82E4 Human Biotinylated Human PD-L1 / B7-H1 (19-134) Protein, His,Avitag™ (recommended for biopanning) (MALS verified)
PDL-H82E4-structure
PDL-H82E4-sds
PDL-R52H6 Rabbit Rabbit PD-L1 / B7-H1 Protein, His Tag
PDL-R52H6-structure
PDL-R52H6-sds
PDL-H5250 Human Human PD-L1 / B7-H1 Protein, Llama IgG2b Fc Tag, low endotoxin
PDL-H5250-structure
PDL-H5250-sds
PDL-H82F2 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™ (MALS verified)
PDL-H82F2-structure
PDL-H82F2-sds
PD1-M52A2 Mouse Mouse PD-L1 / B7-H1 Protein, Mouse IgG2a Fc Tag, low endotoxin
PD1-M52A2-structure
PD1-M52A2-sds
PD1-H82E5 Human Biotinylated Human PD-L1 / B7-H1 Protein, Avitag™,His Tag (recommended for biopanning, MALS verified)
PD1-H82E5-structure
PD1-H82E5-sds
PD1-M82F5 Mouse Biotinylated Mouse PD-L1 / B7-H1 Protein, Fc,Avitag™
PD1-M82F5-structure
PD1-M82F5-sds
PD1-M5220 Mouse Mouse PD-L1 / B7-H1 Protein, His Tag
PD1-M5220-structure
PD1-M5220-sds
PD1-M5251 Mouse Mouse PD-L1 / B7-H1 Protein, Fc Tag
PD1-M5251-structure
PD1-M5251-sds
PD1-H52A3 Human Human PD-L1 / B7-H1 Protein, Mouse IgG1 Fc Tag, low endotoxin (MALS verified)
PD1-H52A3-structure
PD1-H52A3-sds
PD1-C52H4 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-C52H4-structure
PD1-C52H4-sds
PD1-C5253 Cynomolgus / Rhesus macaque Cynomolgus / Rhesus macaque PD-L1 / B7-H1 Protein, Fc Tag
PD1-C5253-structure
PD1-C5253-sds
PD1-H82F3 Human Biotinylated Human PD-L1 / B7-H1 Protein, Fc,Avitag™,His Tag (MALS verified)
PD1-H82F3-structure
PD1-H82F3-sds
PD1-H5282 Human Human PD-L1 / B7-H1 Protein, Strep Tag
PD1-H5282-structure
PD1-H5282-sds
PD1-H5258 Human Human PD-L1 / B7-H1 Protein, Fc Tag (MALS verified)
PD1-H5258-structure
PD1-H5258-sds
PD1-H5229 Human Human PD-L1 / B7-H1 Protein, His Tag (MALS verified)
PD1-H5229-structure
PD1-H5229-sds

Part of Bioactivity data

PD1-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

Flow Cytometry assay shows that Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat.No. PD1-H82F3) can bind to 293 cell overexpressing human PD-1. The concentration of PD-L1 used is 1 μg/mL (Routinely tested).

Protocol
PD1-H82F3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

FACS analysis shows that the binding of Biotinylated Human PD-L1, Fc,Avitag,His Tag (Cat. No. PD1-H82F3) to 293 overexpressing PD-1 was inhibited by increasing concentration of neutralizing anti-PD-1 antibody. The concentration of PD-L1 used is 2 μg/mL. The IC50 is 0.64 μg/mL (Routinely tested).

Protocol
PDL-C82E8-SPR
Human_FcRn_Heterodimer_Protein_SPR

Cynomolgus PD-1, Fc Tag (Cat. No. PD1-C5254) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Biotinylated Cynomolgus / Rhesus macaque PD-L1, His,Avitag (Cat. No. PDL-C82E8) with an affinity constant of 6.59 μM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol
PD1-M5220-SPR
Human_FcRn_Heterodimer_Protein_SPR

Captured Mouse PD-1, Fc Tag (Cat. No. PD1-M5259) on Protein A Chip can bind Mouse PD-L1, His Tag (Cat. No. PD1-M5220) with an affinity constant of 2.16 μM as determined in SPR assay (Biacore T200) (Routinely tested).

Protocol

Customer Reviews

Synonym Name

PD-L1,CD274,B7-H1,PDCD1L1,PDCD1LG1

Background

Programmed cell death 1 ligand 1 (PD-L1) is also known as cluster of differentiation (CD274) or B7 homolog 1 (B7-H1), is a member of the growing B7 family of immune molecules and is involved in the regulation of cellular and humoral immune responses. B7-H1 is a cell surface immunoglobulin superfamily with two Ig-like domains within the extracellular region and a short cytoplasmic domain. PD-L1 is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on activated T-cells, B-cells, dendritic cells, keratinocytes and monocytes. PD-L1 is up-regulated on T- and B-cells, dendritic cells, keratinocytes and monocytes after LPS and IFNG activation and up-regulated in B-cells activated by surface Ig cross-linking. PD-L1 involve in the costimulatory signal, essential for T-cell proliferation and production of IL10 and IFNG, in an IL2-dependent and a PDCD1-independent manner.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Avelumab PF-06834635; MSB-0010718C Approved Merck Serono Bavencio EU Carcinoma, Transitional Cell Merck Europe Bv 2017-03-23 Chordoma; Uterine Cervical Neoplasms; Carcinoma, Hepatocellular; Leukemia, Lymphocytic, Chronic, B-Cell; Melanoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Lymphoma; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Esophageal Squamous Cell Carcinoma; Peritoneal Neoplasms; Colorectal Neoplasms; Vulvar Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Lymphoma, Large B-Cell, Diffuse; Papillomavirus Infections; Carcinoma, Ovarian Epithelial; Glioblastoma; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Carcinoma, Transitional Cell; Hodgkin Disease; Anus Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma; Stomach Neoplasms; Carcinoma, Merkel Cell; Solid tumours Details
Envafolimab KN-035; ASC-22; KN035; ASC22 Approved Suzhou Alphamab Co Ltd Mainland China Microsatellite instability-high cancer; Mismatch Repair Deficient Cancer 3d Medicines (Sichuan) Co Ltd 2021-11-25 Shock, Septic; Solid tumours; Liver Neoplasms; Hepatitis B, Chronic; Mismatch Repair Deficient Cancer; Carcinoma, Renal Cell; Stomach Neoplasms; Esophageal Neoplasms; Sepsis; Microsatellite instability-high cancer; Colorectal Neoplasms; Bile Duct Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Durvalumab 28X28X9-OKV (UNII code); MEDI-4736 Approved Medimmune Llc 英飞凡, Imfinzi United States Small Cell Lung Carcinoma Astrazeneca Uk Ltd 2018-02-16 Esophageal Squamous Cell Carcinoma; Prostatic Neoplasms, Castration-Resistant; Breast Neoplasms; Prostatic Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Carcinoma, Squamous Cell; Lung Neoplasms; Carcinoma, Pancreatic Ductal; Multiple Myeloma; Fallopian Tube Neoplasms; Lymphoma, T-Cell, Cutaneous; Lymphoma; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Melanoma; Carcinoma, Endometrioid; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Solid tumours; Hematologic Neoplasms; Ovarian Neoplasms; Biliary Tract Neoplasms; Kidney Neoplasms; Stomach Neoplasms; Squamous Cell Carcinoma of Head and Neck; Esophageal Neoplasms; Carcinoma; Head and Neck Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Triple Negative Breast Neoplasms; Papillomavirus Infections; Urinary Bladder Neoplasms; Digestive System Neoplasms Details
Sugemalimab WBP-3155; CS-1001 Approved Cstone Pharmaceuticals (Suzhou) Co Ltd 择捷美 Mainland China Carcinoma, Non-Small-Cell Lung Cstone Pharmaceuticals (Suzhou) Co Ltd 2021-12-20 Prostatic Neoplasms; Carcinoma, Hepatocellular; Adenocarcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Lymphoma; Lymphoma, T-Cell; Esophageal Squamous Cell Carcinoma; Colorectal Neoplasms; Lymphoma, Extranodal NK-T-Cell; Ovarian Neoplasms; Urinary Bladder Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Hodgkin Disease; Carcinoma, Renal Cell; Esophageal Neoplasms; Solid tumours; Head and Neck Neoplasms Details
Atezolizumab RO-5541267; 52CMI0WC3Y (UNII code); RG-7446; MPDL-3280A Approved Genentech Inc 泰圣奇, Tecentriq Mainland China Carcinoma, Non-Small-Cell Lung Roche (China) Holding Ltd 2016-05-18 Uterine Neoplasms; Microsatellite Instability; Colorectal Neoplasms; Urologic Neoplasms; Peritoneal Neoplasms; Bile Duct Neoplasms; Genital Neoplasms, Female; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Metastatic breast cancer; Thymoma; Neoplasms, Unknown Primary; Esophageal Squamous Cell Carcinoma; Leukemia, Myeloid, Acute; Sarcoma; Gallbladder Neoplasms; Lymphoma; Carcinoma, Squamous Cell; Urogenital Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Adenocarcinoma; Melanoma; Neoplasm Metastasis; Uterine Cervical Neoplasms; Liposarcoma, Myxoid; Leukemia, Lymphocytic, Chronic, B-Cell; Carcinoma, Transitional Cell; Solid tumours; Ovarian Neoplasms; Head and Neck Neoplasms; Kidney Neoplasms; Hematologic Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Rectal Neoplasms; Carcinoma; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Merkel Cell; Pancreatic Neoplasms; Liver Neoplasms; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; P Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs Phase 1 Clinical Hunan Zhaotai Yongren Biotech Carcinoma, Non-Small-Cell Lung Details
FH-2001 FH-2001 Phase 1 Clinical Shanghai Fosun Pharmaceutical Development Ltd Solid tumours Details
c-Met/PD-L1 CAR-T cell (The Second Hospital of Nanjing Medical University) Phase 1 Clinical The Second Hospital Of Nanjing Medical University Carcinoma, Hepatocellular Details
TT-00420/Atezolizumab Phase 1 Clinical Yaojie Ankang (Nanjing) Technology Co Ltd Gastrointestinal Neoplasms Details
FS 118 FS-118 Phase 2 Clinical Merck Serono, F-Star Hematologic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasm Metastasis Details
GT-90008 GS-19-PLB-1C; GT-90008; GS-19 Phase 1 Clinical Suzhou Kintor Pharmaceuticals Inc Solid tumours Details
BMS-936559 MDX-1105; BMS-936559 Phase 3 Clinical Bristol-Myers Squibb Company Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Shock, Septic; Hodgkin Disease; Sepsis; Multiple Myeloma; Lymphoma, Non-Hodgkin; Carcinoma, Non-Small-Cell Lung; Melanoma Details
CK-301 CK-301 Phase 1 Clinical Dana-Farber Cancer Institute Head and Neck Neoplasms; Carcinoma, Renal Cell; Carcinoma, Merkel Cell; Carcinoma, Transitional Cell; Hodgkin Disease; Mesothelioma; Carcinoma, Squamous Cell; Lymphoma, Non-Hodgkin; Endometrial Neoplasms; Lung Neoplasms; Carcinoma, Small Cell; Carcinoma, Non-Small-Cell Lung; Melanoma Details
IMM-2510 IMM-2510 Phase 1 Clinical ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd Solid tumours Details
Durvalumab/Gefitinib Phase 2 Clinical Medimmune Carcinoma, Non-Small-Cell Lung Details
Q-1802 Q-1802 Phase 1 Clinical Qiyu Biotechnology (Shanghai) Co Ltd Solid tumours Details
SG12473 SG12473; SG-12473 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Solid tumours Details
ACT-001 ACT-001 Phase 2 Clinical Accendatech Glioblastoma; Ganglioglioma; Central Nervous System Neoplasms; Optic Neuritis; Neuromyelitis Optica; Breast Neoplasms; Glioma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma Details
ND-021 ND-021; NM21-1480; CS-2006; CS2006 Phase 2 Clinical Numab Therapeutics Ag, Cstone Pharmaceuticals Solid tumours; Neoplasms; Carcinoma, Non-Small-Cell Lung Details
Emdifen Phase 1 Clinical Tianjin Chase Sun Pharmaceutical Co Ltd, Chinese Academy Of Medical Sciences Solid tumours Details
ABL-501 ABL-501 Phase 1 Clinical Abl Bio Solid tumours Details
Garivulimab BGB-A333 Phase 1 Clinical Beigene Ltd Solid tumours; Neoplasms Details
TQB-2450 APL-502; CBT-502; TQ-B2450 Phase 3 Clinical Cbt Stroke; Carcinoma, Non-Small-Cell Lung; Melanoma; Adenocarcinoma; Uterine Cervical Neoplasms; Lung Neoplasms; Lymphoma; Fallopian Tube Neoplasms; Endometrial Neoplasms; Bile Duct Neoplasms; Peritoneal Neoplasms; Nasopharyngeal Carcinoma; Cholangiocarcinoma; Liver Neoplasms; Carcinoma, Ovarian Epithelial; Hodgkin Disease; Small Cell Lung Carcinoma; Triple Negative Breast Neoplasms; Genital Diseases, Female; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Ovarian Neoplasms; Head and Neck Neoplasms; Biliary Tract Neoplasms; Lymphoma, B-Cell; Solid tumours Details
Recombinant humanized PD-L1 monoclonal antibody (Taizhou Houde Aoke Technology) LP-002 Phase 2 Clinical Taizhou Houde Aoke Technology Co Ltd Solid tumours; Lymphoma, B-Cell; Small Cell Lung Carcinoma; Digestive System Neoplasms; Primary mediastinal B cell lymphoma; Carcinoma, Squamous Cell; Melanoma Details
SKB-337 SKB337; A-337; SKB-337 Phase 1 Clinical Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Solid tumours Details
Anti-CD19 CAR-T cells therapy (Tianjin Mycure Medical Technology) Phase 1 Clinical Tianjin Mycure Medical Technology Co Ltd Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma Details
LY-3415244 LY-3415244 Phase 1 Clinical Eli Lilly And Company Solid tumours; Neoplasms Details
ABSK-043 ABSK043 Phase 1 Clinical Abbisko Therapeutics Solid tumours; Neoplasms Details
Recombinant anti-PD-L1 human monoclonal antibody (Jiansu huaiyu) Phase 1 Clinical Jiangsu Huaiyu Pharmaceutical Co Ltd Solid tumours Details
HB-0025 HB0025 Phase 1 Clinical Huabo Biopharm Co Ltd, Shanghai Huaota Biopharmaceutical Co Ltd Solid tumours Details
FAZ-053 FAZ-053; LAE-005; LAE005 Phase 2 Clinical Novartis Pharma Ag Solid tumours; Triple Negative Breast Neoplasms; Chordoma; Sarcoma, Alveolar Soft Part Details
GR-1405 GR-1405 Phase 3 Clinical Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Zhixiang (Shanghai) Pharmaceutical Technology Co Ltd Head and Neck Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Nasopharyngeal Carcinoma; Lymphoma Details
GS-4224 GS-4224 Phase 1 Clinical Gilead Sciences Inc Solid tumours; Hepatitis B Details
Durvalumab/Selumetinib sulfate Phase 1 Clinical Astrazeneca Plc Neoplasms Details
Pd-1-pik Pd-1-pik Phase 1 Clinical Huashan Hospital Affiliated To Fudan University Glioblastoma Details
PRS-344 PRS-344/ONC0055; PRS-344; PRS-344/S095012; PRS-344S095012; S-095012 Phase 2 Clinical Pieris Pharmaceuticals Inc, Laboratoires Servier Solid tumours Details
GNC-039 GNC-039 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Glioma; Neoplasm Metastasis Details
BJ-005 BJ-005 Phase 1 Clinical Boji Biomedical Technology (Hangzhou) Co Ltd Solid tumours Details
Erfonrilimab KN-046; KN046 Phase 3 Clinical Suzhou Alphamab Co Ltd, Jiangsu Alphamab Biopharmaceuticals Co Ltd Solid tumours; Esophageal Neoplasms; Stomach Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Breast Neoplasms; Thymus Neoplasms; Carcinoma, Pancreatic Ductal; Lymphoma; Carcinoma, Squamous Cell; Esophageal Squamous Cell Carcinoma; Thymoma; Carcinoma, Non-Small-Cell Lung; Carcinoma, Hepatocellular; Gastrointestinal Neoplasms Details
PF-07257876 Phase 1 Clinical Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
FPT-155 CD80-Fc; FPT-155 Phase 1 Clinical Five Prime Therapeutics Solid tumours Details
Sudubrilimab HS-636 Phase 2 Clinical Zhejiang Hisun Pharmaceutical Co Ltd Triple Negative Breast Neoplasms; Primary mediastinal B cell lymphoma Details
Human source and Fc engineered monoclonal antibody (MabSpace) MSB-2311 Phase 1 Clinical Mabspace Biosciences Co Ltd Solid tumours Details
BMS-986189 BMS-189; BMS-986189; PD-L1-Milla; BMS-986189-07 Phase 1 Clinical Bristol-Myers Squibb Company Sepsis Details
ALPN-202 ALPN-202 Phase 1 Clinical Alpine Immune Sciences Solid tumours; Lymphoma Details
IMM2505 IMM2505 Phase 1 Clinical Shenghe (China) Biopharmaceutical Co Ltd Solid tumours Details
Opucolimab HLX-20 Phase 1 Clinical Shanghai Henlius Biotech Co Ltd Solid tumours; Neoplasms Details
BR-102 BR102 Phase 1 Clinical Solid tumours Details
89Zr-KN035（Wuxi No. 4 People's Hospital） Clinical Wuxi No. 4 People Solid tumours Details
QLF31907 QLF31907; QLF-31907 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
Carrizumab Phase 2 Clinical Esophageal Neoplasms; Stomach Neoplasms; Adenocarcinoma Details
IMC-001 IMC-001; STI-3031; STI-A1015 Phase 2 Clinical Sorrento Therapeutics Solid tumours; Lymphoma, T-Cell, Peripheral; Biliary Tract Neoplasms; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Extranodal NK-T-Cell; Neoplasm Metastasis; Gastrointestinal Neoplasms Details
LOR-S03 CDX-527 Phase 1 Clinical Celldex Therapeutics Solid tumours; Liver Neoplasms; Ovarian Neoplasms; Head and Neck Neoplasms; Stomach Neoplasms; Carcinoma, Renal Cell; Esophageal Neoplasms; Microsatellite instability-high cancer; Urinary Bladder Neoplasms; Cholangiocarcinoma; Breast Neoplasms; Peritoneal Neoplasms; Colorectal Neoplasms; Fallopian Tube Neoplasms; Carcinoma, Non-Small-Cell Lung Details
TJ-L14B ABL-503; TJ-L14B/ABL503; ABL503 Phase 1 Clinical I-Mab Biopharma Co Ltd Solid tumours Details
Dual-targeting HER2 and PD-L1 CAR-T Cell Therapy (Sichuan University) Phase 1 Clinical Sichuan University Peritoneal Neoplasms Details
PM-8001 6MW3111; PM-8001 Phase 2 Clinical Biotheus Inc Solid tumours; Lung Neoplasms Details
MT-6402 Phase 1 Clinical Molecular Templates Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung Details
MVR-C5252 C-5252; MVR-C5252 Phase 1 Clinical Immvira Co Ltd Solid tumours; Glioblastoma; Ganglioglioma; Brain Neoplasms Details
Recombinant human anti-PD-L1 monoclonal antibody (Guilin Sanjin) Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene (Suzhou) Ltd, Dragonboat Biopharmaceutical, Baifan Biotechnology (Shanghai) Co Ltd Carcinoma, Renal Cell; Urinary Bladder Neoplasms; Penile Neoplasms Details
PM-1003 PM1003 Phase 2 Clinical Biotheus Inc Solid tumours Details
MCLA-145 MCLA-145 Phase 1 Clinical Incyte Corp, Merus Solid tumours Details
IGV-001 IGV-001 Phase 2 Clinical Thomas Jefferson University Glioblastoma Details
FS-222 FS-222 Phase 1 Clinical F-star Beta Ltd Neoplasm Metastasis Details
18F-BMS-986192 BMS-986192-[18F] Clinical Bristol-Myers Squibb Company Neoplasms Details
89Zr-durvalumab Phase 2 Clinical Radboud University Nijmegen Head and Neck Neoplasms Details
Recombinant anti-PD-L1/TGF-β bispecific antibody Y101D; Y-101D Phase 1 Clinical Wuhan Yzy Biopharma Co Ltd Solid tumours Details
IBI-318(Innovent Biologics/Eli Lilly And Company) LY-3434172; LY3434172; IBI-318 Phase 2 Clinical Innovent Biologics(Suzhou) Co Ltd, Eli Lilly And Company Small Cell Lung Carcinoma; Lymphoma, Extranodal NK-T-Cell; Carcinoma, Squamous Cell; Carcinoma, Hepatocellular Details
IBI-323(Innovent Biologics) IBI-323 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours Details
QLS31901 QLS-31901; QLS31901 Phase 1 Clinical Qilu Pharmaceutical Co Ltd Neoplasms Details
CHECKvacc CF33-hNIS-antiPDL1 Phase 1 Clinical Imugene Ltd, City Of Hope National Medical Center Triple Negative Breast Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
GNC-035 quadr-specific antibody（baili） GNC-035 Phase 1 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer Details
HLX-301 HLX-301 Phase 2 Clinical Shanghai Henlius Biologics Co Ltd Solid tumours; Carcinoma, Non-Small-Cell Lung Details
Manelimab BCD-135 Phase 1 Clinical Biocad Carcinoma, Renal Cell; Neoplasms; Urinary Bladder Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Pacmilimab CX-072 Phase 2 Clinical Cytomx Therapeutics Solid tumours; Triple Negative Breast Neoplasms; Breast Neoplasms; Lymphoma; Melanoma Details
Lodapolimab LY-3300054 Phase 1 Clinical Eli Lilly And Company Solid tumours; Skin Melanoma; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Microsatellite instability-high cancer; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung Details
ATG-101 ATG-101 Phase 1 Clinical Antengene Corporation Co Ltd Hematologic Neoplasms; Solid tumours; Lymphoma, Non-Hodgkin Details
AN-4005 AN-4005 Phase 1 Clinical Hangzhou Adlai Nortye Biomedical Technology Co Ltd Solid tumours; Neoplasms; Lymphoma Details
TST-005 TST-005; TST005 Phase 1 Clinical Mabspace Biosciences Co Ltd Neoplasms Details
ADG-104 ADG-104; ADG104 Phase 2 Clinical Guilin Sanjin Pharmaceutical Co Ltd, Adagene Inc Neoplasms Details
SHS-009 SHS-009; SH009; SH-009 Phase 1 Clinical Nanjing Sanhome Pharmaceutical Co Ltd Neoplasms Details
BPI-371153 BPI-371153 Phase 1 Clinical Betta Pharmaceuticals Co Ltd Lymphoma Details
TS-1905 TS-1905; LY-01019; BA-1201 Phase 1 Clinical Shandong Boan Biotechnology Co Ltd Solid tumours; Biliary Tract Neoplasms; Stomach Neoplasms; Papillomavirus Infections; Carcinoma, Non-Small-Cell Lung Details
INBRX-105 ES101; INBRX-105 Phase 2 Clinical Inhibrx Solid tumours; Thoracic Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Stomach Neoplasms; Small Cell Lung Carcinoma; Carcinoma, Transitional Cell; Esophageal adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
JS-003 JS-003 Phase 1 Clinical Shanghai Junshi Biosciences Co Ltd Solid tumours Details
RC-98 RC-98; RC98 Phase 2 Clinical RemeGen Co Ltd Solid tumours Details
99mTc-NM-01 99mTc-NM-01 Phase 2 Clinical Nanomab Technology Ltd Carcinoma, Non-Small-Cell Lung Details
GNC-038 GNC-038 Phase 2 Clinical Sichuan Baili Pharmaceutical Co Ltd Solid tumours; Lymphoma, Large B-Cell, Diffuse; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin Details
Simridarlimab IBI-322 Phase 1 Clinical Innovent Biologics(Suzhou) Co Ltd Solid tumours; Hematologic Neoplasms; Bone Marrow Neoplasms; Neoplasms; Leukemia, Myeloid, Acute Details
MAX-10181 MAX-10181; MAX-1 Phase 1 Clinical Guangzhou Maxinovel Pharmaceiticals Co Ltd Solid tumours Details
6MW-3211 6MW3211; 6MW-3211 Phase 2 Clinical Mabwell (Shanghai) Bioscience Co Ltd Neoplasms Details
INCB-086550 INCB-086550; INCB-86550 Phase 2 Clinical Incyte Corp Solid tumours; Carcinoma, Renal Cell; Carcinoma; Carcinoma, Non-Small-Cell Lung; Melanoma; Carcinoma, Hepatocellular Details
RG-6084 RG-6084; RO-7191863 Phase 1 Clinical F. Hoffmann-La Roche Ltd Hepatitis B Details
TQB-2858 TQB-2858 Phase 2 Clinical Nanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group Pancreatic Neoplasms; Sarcoma; Endometrial Neoplasms; Uterine Cervical Neoplasms Details
Cosibelimab TG-1501; CK-301 Phase 3 Clinical Tg Therapeutics Lymphoma; Carcinoma, Non-Small-Cell Lung Details
CA-170 AUPM-170; CA-170 Phase 1 Clinical Aurigene Solid tumours Details
Acasunlimab GEN1046; BNT-311; DuoBody-PD-L1x4-1BB; PD-L1x4-1BB Phase 2 Clinical Biontech Se, Genmab Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms Details
SGN-PDL1V SGN-PDL1V Phase 1 Clinical Seagen Inc Ovarian Neoplasms; Squamous Cell Carcinoma of Head and Neck; Neoplasms; Esophageal Squamous Cell Carcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung Details
BAT-7104 BAT-7104 Phase 1 Clinical Bio-Thera Solutions Ltd Solid tumours; Neoplasms Details
Retlirafusp alfa SHR-1701 Phase 3 Clinical Jiangsu Hengrui Medicine Co Ltd Solid tumours; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Rectal Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Prostatic Neoplasms; Nasopharyngeal Carcinoma; Colorectal Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
LBL-024 LBL024; LBL-024 Phase 2 Clinical Nanjing Leads Biolabs Co Ltd Solid tumours Details
ASC-61 ASC-61 Phase 1 Clinical Ascletis Pharma Inc Solid tumours; Neoplasms Details
KD-033 KD-033 Phase 1 Clinical Takeda Pharma Solid tumours Details
Bintrafusp alfa M-7824; GSK-4045154; MSB-0011359C Phase 3 Clinical Merck Serono Biliary Tract Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Cholangiocarcinoma; Gallbladder Neoplasms; Lung Neoplasms; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung Details
QL-415 QL-415 Phase 1 Clinical Neoplasms Details
QL-301 QL-301 Phase 1 Clinical Neoplasms Details
PD-L1/CTLA4 bispecific monoclonal antibody (Changhai Hospital) Phase 2 Clinical Changhai Hospital Of Shanghai Pancreatic Neoplasms Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Email
Email
order@acrobiosystems.com
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA
linkedin twitter facebook youtube

Leave a message

Copyright © 2017 ACROBiosystems. All Rights Reserved
中文网站|Related Links|Privacy Policy|Terms and Conditions|Legal|Sitemap